TOKYO - In a step that will effectively allow Takeda Pharmaceutical Co. Ltd. to concentrate on developing its growing innovative business, Japan's leading pharma company has entered into a definitive agreement to set up a minority-owned joint venture in Japan with Teva Pharmaceutical Industries Ltd., into which it will transfer its portfolio of mature products.
The as yet unnamed JV will be 51% owned by Teva and 49% by Takeda, but headquarters location, investment amounts, capitalization and other details have so far not been disclosed
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?